Mérieux Equity Partners

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. From Uganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.

Curea Medical specializes in manufacturing advanced wound care dressings. Their products, which include wound dressings, skin protection films, and tubular bandages, are designed to efficiently manage wound exudate, promote healing, and enhance patient outcomes. The company's proprietary SuperCore technology enables rapid absorption and secure retention of liquids, making their dressings particularly effective for managing diverse wound types, such as exuding wounds, burns, and those with sensitive skin.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions (MVO) in patients experiencing severe heart attacks. The company has created a controlled flow infusion system that measures the degree of MVO through a proprietary concept known as dynamic microvascular resistance. This system provides interventional cardiologists with critical data that can be compared to post-procedure contrast-enhanced magnetic resonance imaging. By enabling accurate diagnosis and treatment of MVO, CorFlow aims to reduce both short- and long-term complications in heart attack patients, addressing significant unmet medical needs in cardiovascular care.

Prothea Technologies is a private medical technology company specializing in lung cancer diagnostics and treatment. Its innovative solution combines a microendoscope with advanced image processing, enabling hospitals to perform both biopsy and therapy in a single visit, enhancing visualization and improving patient outcomes.

Innosyn uses flow chemistry, bio- and chemocatalysis to produce chemicals product or enzymes along with optimization of plant processes.

Labquality is a provider of quality controls and reference materials aimed at ensuring quality assurance in medical laboratories and point of care testing. The company offers a range of services, including certification, regulatory consulting, and traceable quality controls, as well as calibrator reference materials. These services are designed to enhance patient safety through independent quality assessments and support clients in navigating industry regulations, quality management, and obtaining marketing authorizations. By focusing on the healthcare sector, Labquality plays a crucial role in promoting high standards within medical technology industries.

Amyl Therapeutics is a preclinical stage biotechnology company focused on developing therapeutics for various forms of amyloidosis. The company utilizes a novel mechanism to bind to the amyloid folds of toxic protein aggregates, including antibody light chain (AL) and transthyretin (TTR) aggregates, which contribute to systemic amyloidosis. Additionally, Amyl Therapeutics targets amyloid-β (Aβ), Tau, and α-synuclein aggregates associated with neurodegenerative diseases such as Alzheimer's and Parkinson's. By addressing multiple misfolded proteins responsible for both peripheral and central nervous system pathologies, the company aims to provide effective therapies that can prevent the accumulation of harmful protein aggregates in organs and the brain, offering new treatment options for patients suffering from these debilitating conditions.

Broken String Biosciences is focused on creating a sequencing platform that enhances the assessment of genome stability, aiming to facilitate the development of safer cell and gene therapies. The company integrates advanced sequencing techniques with bioinformatics and artificial intelligence, enabling healthcare professionals to utilize a data-driven approach for the safe introduction of innovative medicines. Through its novel tools, Broken String Biosciences seeks to unlock advancements in therapeutic options, contributing to the evolution of medical treatments.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Mablink Bioscience is a biotechnology company focused on developing a new class of cancer therapies known as Antibody Drug Conjugates (ADCs). The company specializes in designing homogeneous, plasma-stable ADCs that maintain their original pharmacological properties while achieving a high drug-to-antibody ratio (DAR). This innovative approach aims to provide healthcare professionals with enhanced treatment options for cancer patients, ultimately improving therapeutic outcomes.

AstriVax is focused on developing novel vaccines that address significant challenges in the field of vaccinology. The company aims to create vaccines that minimize cold chain requirements while providing broad and long-lasting protection against a range of viruses and other pathogens. By pursuing initial clinical validation of its platform technology, AstriVax seeks to establish a comprehensive vaccination pipeline to enhance treatment options in the healthcare sector.

Cairdac is a medtech startup focused on developing an innovative leadless pacing system that utilizes a self-sustaining power technology. The company has achieved a significant milestone by creating the first self-sustaining pacemaker with a lifespan exceeding 15 years, leveraging a proprietary piezoelectric energy harvester in conjunction with a miniaturized power management circuit. Their unique product, the ALPS, is an autonomous and endoscopically implanted leadless pacemaker designed to harness the heart's kinetic energy for power. By integrating disruptive technologies into traditional pacemaker designs, Cairdac aims to provide a cost-effective solution that addresses the evolving needs of patients and healthcare professionals while enhancing the overall quality of life for those requiring cardiac rhythm management.

Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGS has had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.

Dental Monitoring, founded in 2014 by CEO Philippe Salah, is a leader in remote dental monitoring solutions, driven by advanced artificial intelligence. The company has grown significantly, expanding its international presence with over 400 employees across Europe, the USA, Australia, Hong Kong, and Singapore. Its innovative platform is designed to empower dental professionals by creating automated workflows and patient communication protocols. Utilizing patented hardware, Dental Monitoring enables patients to submit high-quality intraoral images at their convenience, allowing for precise analysis of treatment compatibility. This technology enhances practice efficiency and enables effective virtual monitoring of various dental cases, ultimately improving patient care and outcomes.

Amyl Therapeutics is a preclinical stage biotechnology company focused on developing therapeutics for various forms of amyloidosis. The company utilizes a novel mechanism to bind to the amyloid folds of toxic protein aggregates, including antibody light chain (AL) and transthyretin (TTR) aggregates, which contribute to systemic amyloidosis. Additionally, Amyl Therapeutics targets amyloid-β (Aβ), Tau, and α-synuclein aggregates associated with neurodegenerative diseases such as Alzheimer's and Parkinson's. By addressing multiple misfolded proteins responsible for both peripheral and central nervous system pathologies, the company aims to provide effective therapies that can prevent the accumulation of harmful protein aggregates in organs and the brain, offering new treatment options for patients suffering from these debilitating conditions.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

AcuSurgical is a startup focused on advancing vitreo-retinal surgery through the development of a robotic surgical assistant. This innovative device is designed to enhance the precision and effectiveness of eye operations, particularly for treating retinal diseases like age-related macular degeneration. By providing surgeons with advanced tools to filter tremors and improve visualization during procedures, AcuSurgical aims to improve outcomes and increase the success rates of retinal surgeries.

Plantex is a manufacturer specializing in plant extracts for various applications, including nutraceuticals, food, animal nutrition, and cosmetics. The company produces a range of standardized products such as dry, liquid, soft, glycolic, and hydro-glycerinated extracts derived from natural raw materials. By leveraging its expertise in plant knowledge and production, Plantex aims to fulfill client requirements for authenticity, efficiency, and innovation in formulations, solubilization, and compression.

keepMED Ltd. is a company focused on developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA), a condition marked by repeated episodes of upper airway obstruction during sleep. The company's primary product, keePAP, is a lightweight and unobtrusive wearable device that includes a nasal interface and a miniature battery-operated control unit. Founded in 2012 and based in Rishon Le Zion, Israel, keepMED aims to provide effective treatment options for individuals suffering from OSA.

TARA Biosystems, Inc. is a biotechnology company focused on developing organ-on-a-chip technology, specifically human cardiac tissue models, to enhance drug discovery and safety assessments. Founded in 2014 and based in the United States, the company utilizes stem cell-derived cardiac tissue that mimics adult physiological conditions, enabling precise measurement of cardiac functionality. This innovative platform aims to facilitate the faster and safer development of new therapies by providing predictive in vitro models that can assess the effects of drug compounds on heart function without the need for human testing. Through its advanced technology, TARA Biosystems seeks to improve the health of patients by enabling more reliable assessments of cardiac drug efficacy and safety.

Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. From Uganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.

ADDMEDICA is a French medical product company focused on developing and marketing innovative and personalized solutions for patients with rare diseases and serious medical conditions. The company addresses significant unmet medical needs within niche markets by creating specialized medical products that can be used alongside or as alternatives to traditional drugs. ADDMEDICA's expertise allows it to target these unique medical products globally, ensuring they are accessible to health professionals and patients alike. The company's portfolio includes treatments for conditions such as sickle cell disease, emphasizing a commitment to delivering high medical value to physicians, patients, and managed care organizations.

Mabtech AB is a biotechnology company based in Stockholm, Sweden, founded in 1986. The company specializes in the development, manufacturing, and marketing of monoclonal antibodies and various assay kits, including those for enzyme-linked immunoassays such as ELISA, ELISpot, and FluoroSpot. Mabtech's product range includes monoclonal antibodies for a variety of applications, as well as specialized kits for detecting cytokines and other immunological molecules in biological samples from multiple species, including humans and various animals. The company aims to support the global scientific community by providing efficient tools that streamline the biomedical research process. Mabtech operates internationally, with locations in the United States, Australia, Germany, and France, and offers its products online. It is a subsidiary of Mabtech Group AB.

Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing bifunctional antibody therapies aimed at treating hematologic malignancies. Founded in 2012 and based in South San Francisco, California, the company utilizes its proprietary ReSTORE platform to create dual-action biologics that enhance the patient's immune response against cancer. These therapies are designed to relieve immune suppression while activating T cells, thereby promoting the destruction of tumor cells and their precursors. The platform emphasizes avidity, target selectivity, and safety, and can be engineered to include additional functionalities for targeting solid tumors. As a subsidiary of Affimed N.V., Amphivena Therapeutics aims to provide innovative treatment options for patients facing blood cancers.

Keranova S.A., founded in 2015 and based in Saint Etienne, France, along with an office in Vénissieux, specializes in designing and developing innovative surgical equipment for ophthalmology, specifically targeting the anterior segment of the eye. The company focuses on creating advanced surgical instruments that aim to enhance existing semi-manual, operator-dependent procedures in ophthalmic surgery. Keranova's patented technology allows for a novel approach to anterior segment surgery, utilizing automated equipment equipped with vision, intelligent software, and precise robotic movements. This innovation significantly reduces the need for manual intervention, thereby improving the reproducibility and efficiency of surgical procedures.

Doc Generici s.r.l. is an Italian company based in Milan that specializes in the production and distribution of generic medicines. Established in 1996 following the approval of legislation that facilitated the use of equivalent medicines, the company offers a diverse range of therapeutic drugs, including those for anti-infective, anti-neoplastic, cardiovascular, dermatological, gastrointestinal, neurological, ophthalmological, respiratory, and musculoskeletal conditions. In addition to pharmaceuticals, Doc Generici provides nutritional supplements and medical devices. The company emerged as a key player in the generic medicines market, particularly after distribution began in 2001 when regulations required pharmacists to offer lower-priced equivalent medications. As a subsidiary of Diocle S.p.A., Doc Generici is committed to maintaining high-quality standards while ensuring affordability for patients seeking effective treatment options.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Omnipharm, is a supplier of natural ingredients made in France

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Biobest N.V. develops and supplies natural crop care systems. It specializes in bumblebee pollination and sustainable crop management. The company offers biological pollination products, such as bumblebees; biological control products, which include beneficial insects and mites, beneficial nematodes, and biopesticides; and monitoring and scouting products, including sticky traps and rolls, pheromone traps, and pheromone lures and attractants to growers.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Stiplastics S.A.S. specializes in the design, development, and manufacturing of medical devices for the healthcare sector, both in France and internationally. Established in 1985 and headquartered in Beauvoir-en-Royans, the company offers a diverse range of products, including distributor pumps, tamper-proof containers, caps, closures, cosmetic spatulas, nozzles, droppers, measuring scoops, and various packaging solutions. Additionally, it provides pharmaceutical packaging products, carrying cases for biological samples, and pillboxes. Stiplastics S.A.S. distributes its offerings through a comprehensive catalog, catering to the needs of the healthcare industry.

Laboratoires Ineldea, based in Carros, France, specializes in the formulation, development, manufacturing, and marketing of a wide range of products, including nutritional supplements, health foods, organic cosmetics, and nutraceutical solutions. Established in 2003 by a team with over 20 years of experience in natural products, the company leverages recognized technical and scientific expertise to deliver innovative health solutions. With a diverse product portfolio exceeding 400 references, Laboratoires Ineldea is committed to quality and consistency, earning the trust of healthcare professionals and consumers alike. The company's products are marketed through pharmacies, drugstores, specialty stores, and health professionals across international markets, focusing on meeting the unique health needs of individuals at various life stages.

PhysioAssist, founded in 2012, is a company focused on developing medical devices aimed at treating obstructive respiratory diseases. By integrating expertise in the physics of materials, signal processing, and life sciences, PhysioAssist has created innovative solutions that enhance the quality of life for patients. Their patented technology modifies the physical properties of mucus, facilitating the mobilization and removal of secretions, which allows healthcare professionals to provide effective treatment for bronchial congestion. The design and ergonomics of their devices have been meticulously optimized for daily use in patient care, ensuring they meet the practical needs of both patients and healthcare providers.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

LNA Sante is a global health player with nearly 70 establishments in France and Belgium. Nursing homes (EHPAD and MRS), Follow-up care and rehabilitation (SSR), Home hospitalization structures (HAD), Health centers, Psychiatric clinic. Our mission is to improve the quality of life for people who are temporarily or permanently vulnerable, in a welcoming and caring environment, suitable for everyone and for all ages. Our commitment "To care and take care" of you or your loved ones daily, patients and residents who are welcomed in our structures in France or in Belgium. A mission and commitment shared by all our teams.

Seqens is a provider of pharmaceutical ingredients and specialty chemicals headquartered in Ecully, France. The company specializes in the synthesis of active pharmaceutical ingredients (APIs) including aspirin, paracetamol, salicylic acid, and para-aminophenol, along with a range of specialty chemicals such as soda ash, sodium bicarbonate, phenol, oxygenated solvents, and ferric chloride. Seqens serves various demanding industries, including healthcare, electronics, cosmetics, food, and household cleaning products. The company is known for its market responsiveness and ability to deliver customized solutions tailored to the specific needs of its customers.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

keepMED Ltd. is a company focused on developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA), a condition marked by repeated episodes of upper airway obstruction during sleep. The company's primary product, keePAP, is a lightweight and unobtrusive wearable device that includes a nasal interface and a miniature battery-operated control unit. Founded in 2012 and based in Rishon Le Zion, Israel, keepMED aims to provide effective treatment options for individuals suffering from OSA.

Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. From Uganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.

Kalila Medical focuses on developing advanced catheter technologies for vascular and intracardiac access. The company specializes in a platform of steerable sheaths designed to enhance precision during catheter-based procedures, particularly for atrial fibrillation ablation. Its initial product line includes sheaths compatible with both 8Fr and 12Fr ablation catheters, offering improved torque and tip control essential for effective catheter delivery and lesion formation. Beyond atrial fibrillation, Kalila's technology has applications in various endovascular procedures, including mitral valve repair, closure of atrial septal defects and patent foramen ovale, left atrial appendage closure, transseptal puncture, and left ventricular lead placement. Founded in 2010, Kalila Medical emerged from Shifamed LLC, a medical device incubator based in Silicon Valley.

Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.

Lavorel Medicare is a service provider focused on nursing care, offering support both at home and in specialized care units. The company operates a German subsidiary, Bonitas GmbH, which employs approximately 3,000 staff members dedicated to providing medical assistance to disabled patients with chronic illnesses or genetic conditions. Bonitas GmbH serves over 2,000 patients across Germany, operating through a network of 50 agencies to ensure comprehensive care and support.

HumanCharger is a developer of innovative light therapy devices that utilize a patented mechanism to enhance mental performance and well-being. By delivering calibrated white light through the ear canals, the device stimulates photosensitive proteins in the brain. This unique approach allows users to experience benefits such as increased energy levels, improved mood, heightened mental alertness, and reduced symptoms of seasonal affective disorder. The device is designed to be portable, making it convenient for daily use, with just 12 minutes of application recommended to achieve significant positive effects.

Lavorel Medicare is a service provider focused on nursing care, offering support both at home and in specialized care units. The company operates a German subsidiary, Bonitas GmbH, which employs approximately 3,000 staff members dedicated to providing medical assistance to disabled patients with chronic illnesses or genetic conditions. Bonitas GmbH serves over 2,000 patients across Germany, operating through a network of 50 agencies to ensure comprehensive care and support.

Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.

Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.

Advencis is a developer and manufacturer of lab instruments and medical devices.The company has developed Advencis Bio-System Incubator, a modular system of early detection which is fully automated for industrial microbiology (food and pharmaceutical industries) and clinical markets. The system provides highly sensitive detection of the microorganisms on agar plates and on filter-based devices. It also provides Advencis Bio-System Software which is a real time monitoring application.

Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.

AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.

Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.

QuantaLife, Inc. is a biotechnology startup focused on developing and marketing innovative nucleic acid testing technologies for various sectors, including life science research, clinical diagnostics, and personalized medicine. The company offers advanced genetic analysis platforms designed to facilitate rapid detection and quantification of nucleic acids in complex samples using a flexible, automated instrument. QuantaLife's proprietary testing method significantly enhances performance compared to existing technologies while reducing costs, making it a valuable tool for researchers and clinicians. By providing a cost-effective and high-resolution platform for validating next-generation sequencing discoveries, QuantaLife enables the exploration of complex genetic landscapes, the identification of new disease associations, and the advancement of molecular diagnostic tests.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGS has had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.